Department of Pediatrics, Stanford University School of Medicine, Lucile Packard Children's Hospital Stanford, Palo Alto, CA.
Pediatric Heart Lung Center, Department of Pediatrics, University of Colorado Denver Anschutz Medical Center and Children's Hospital Colorado, Aurora, CO.
J Pediatr. 2023 Jan;252:131-140.e3. doi: 10.1016/j.jpeds.2022.08.027. Epub 2022 Aug 24.
To characterize distinct comorbidities, outcomes, and treatment patterns in children with Down syndrome and pulmonary hypertension in a large, multicenter pediatric pulmonary hypertension registry.
We analyzed data from the Pediatric Pulmonary Hypertension Network (PPHNet) Registry, comparing demographic and clinical characteristics of children with Down syndrome and children without Down syndrome. We examined factors associated with pulmonary hypertension resolution and a composite outcome of pulmonary hypertension severity in the cohort with Down syndrome.
Of 1475 pediatric patients with pulmonary hypertension, 158 (11%) had Down syndrome. The median age at diagnosis of pulmonary hypertension in patients with Down syndrome was 0.49 year (IQR, 0.21-1.77 years), similar to that in patients without Down syndrome. There was no difference in rates of cardiac catheterization and prescribed pulmonary hypertension medications in children with Down syndrome and those without Down syndrome. Comorbidities in Down syndrome included congenital heart disease (95%; repaired in 68%), sleep apnea (56%), prematurity (49%), recurrent respiratory exacerbations (35%), gastroesophageal reflux (38%), and aspiration (31%). Pulmonary hypertension resolved in 43% after 3 years, associated with a diagnosis of pulmonary hypertension at age <6 months (54% vs 29%; P = .002) and a pretricuspid shunt (65% vs 38%; P = .02). Five-year transplantation-free survival was 88% (95% CI, 80%-97%). Tracheostomy (hazard ratio [HR], 3.29; 95% CI, 1.61-6.69) and reflux medication use (HR, 2.08; 95% CI, 1.11-3.90) were independently associated with a composite outcome of severe pulmonary hypertension.
Despite high rates of cardiac and respiratory comorbidities that influence the severity of pulmonary hypertension, children with Down syndrome-associated pulmonary hypertension generally have a survival rate similar to that of children with non-Down syndrome-associated pulmonary hypertension. Resolution of pulmonary hypertension is common but reduced in children with complicated respiratory comorbidities.
在一个大型的多中心儿科肺动脉高压注册研究中,描述患有唐氏综合征的儿童与肺动脉高压相关的不同合并症、结局和治疗模式。
我们分析了儿科肺动脉高压网络(PPHNet)注册数据库的数据,比较了患有唐氏综合征和不患有唐氏综合征的儿童的人口统计学和临床特征。我们检查了与唐氏综合征组中肺动脉高压缓解和肺动脉高压严重程度复合结局相关的因素。
在 1475 例患有肺动脉高压的儿科患者中,有 158 例(11%)患有唐氏综合征。唐氏综合征患者肺动脉高压的中位诊断年龄为 0.49 岁(IQR,0.21-1.77 岁),与无唐氏综合征患者相似。唐氏综合征患儿与无唐氏综合征患儿的心脏导管检查和肺动脉高压药物治疗率无差异。唐氏综合征的合并症包括先天性心脏病(95%;其中 68%已修复)、睡眠呼吸暂停(56%)、早产(49%)、反复呼吸道感染(35%)、胃食管反流(38%)和吸入(31%)。3 年后,43%的患者的肺动脉高压得到缓解,与 6 个月龄前诊断肺动脉高压(54%比 29%;P=0.002)和存在三尖瓣前向分流(65%比 38%;P=0.02)相关。5 年无移植生存率为 88%(95%CI,80%-97%)。气管造口术(危险比[HR],3.29;95%CI,1.61-6.69)和反流药物治疗(HR,2.08;95%CI,1.11-3.90)与严重肺动脉高压的复合结局独立相关。
尽管唐氏综合征患儿存在影响肺动脉高压严重程度的心脏和呼吸合并症的高发生率,但患有唐氏综合征相关肺动脉高压的儿童的生存率与患有非唐氏综合征相关肺动脉高压的儿童相似。尽管肺动脉高压的缓解较为常见,但存在复杂呼吸合并症的儿童缓解率较低。